Vimta Labs posts Q4 FY25 PAT at Rs. 18.31 Cr

Vimta Labs has reported total income of Rs. 96.08 crores during the period ended March 31, 2025

CHMP recommends EU label update for Roche’s Phesgo to allow administration outside of clinical settings

Phesgo label expansion delivers on patients’ preference for at-home administration and is an important step in freeing up cancer care capacity in clinical settings

USFDA inspects Marksans’s subsidiary Time-Cap Laboratories' manufacturing facility

The Subsidiary has received one inspectional observation in Form 483

Strides receives USFDA approval for anti-inflammatory Celecoxib Capsules

Celecoxib Capsules approval complements Strides’ existing products to serve a broader patient base

Merck breaks ground on new $1 billion Biologics Center of Excellence in Delaware, US

Merck Wilmington Biotech will serve as a launch and commercial production facility and the future U.S. home for KEYTRUDA

Vimta Labs to invest Rs. 50 crores to Biologics CDMO business foray

The foray into this new segment will help Vimta to enter into the growing CDMO business of biologics and peptides

Morepen to launch new fatty lever drug ‘Resmetirom’

Biocon Biologics receives positive CHMP opinions for biosimilar Denosumab in Europe

The positive opinions are based on applications submitted by Biosimilar Collaborations Ireland Limited

CuraTeQ Biologics receives positive opinion for biosimilar Dazublys from EMA

Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein

Dr. Lal Path Labs posts Q4 FY25 consolidated PAT at Rs. 154.8 Cr

The company has reported total income of Rs. 628.4 crores during the period ended March 31, 2025